Interpreting epidemiological research:: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1

被引:120
作者
Eng, C
Brody, LC
Wagner, TMU
Devilee, P
Vijg, J
Szabo, C
Tavtigian, SV
Nathanson, KL
Ostrander, E
Frank, TS
机构
[1] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Tzagournis MRF, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA
[4] Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge, England
[5] NIH, Bethesda, MD 20892 USA
[6] Univ Vienna, Div Senol, Dept Obstet & Gynecol, A-1010 Vienna, Austria
[7] Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands
[8] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands
[9] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA
[10] Univ Texas, Hlth Sci Ctr, San Antonio, TX USA
[11] Int Agcy Res Canc, F-69372 Lyon, France
[12] Myriad Genet Labs, Salt Lake City, UT USA
[13] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[14] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
关键词
BRCA1; mutation detection; cancer genetics;
D O I
10.1136/jmg.38.12.824
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
While sequence analysis is considered by many to be the most sensitive method of detecting unknown mutations in large genes such as BRCA1, most published estimates of the prevalence of mutations in this gene have been derived from studies that have used other methods of gene analysis. In order to determine the relative sensitivity of techniques that are widely used in research on BRCA1, a set of blinded samples containing 58 distinct mutations were analysed by four separate laboratories. Each used one of the following methods: single strand conformational polymorphism analysis (SSCP), conformation sensitive gel electrophoresis (CSGE), two dimensional gene scanning (TDGS), and denaturing high performance liquid chromatography (DHPLC). Only the laboratory using DHPLC correctly identified each of the mutations. The laboratory using TDGS correctly identified 91% of the mutations but produced three apparent false positive results. The laboratories using SSCP and CSGE detected abnormal migration for 72% and 76% of the mutations, respectively, but subsequently confirmed and reported only 65% and 60% of mutations, respectively. False negatives therefore resulted not only from failure of the techniques to distinguish wild type from mutant, but also from failure to confirm the mutation by sequence analysis as well as from human errors leading to misreporting of results. These findings characterise sources of error in commonly used methods of mutation detection that should be addressed by laboratories using these methods. Based upon sources of error identified in this comparison, it is likely that mutations in BRCA1 and BRCA2 are more prevalent than some studies have previously reported. The findings of this comparison provide a basis for interpreting studies of mutations in susceptibility genes across many inherited cancer syndromes.
引用
收藏
页码:824 / 833
页数:10
相关论文
共 37 条
  • [1] A SUGGESTED NOMENCLATURE FOR DESIGNATING MUTATIONS
    BEAUDET, AL
    TSUI, LC
    [J]. HUMAN MUTATION, 1993, 2 (04) : 245 - 248
  • [2] BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
    Couch, FJ
    DeShano, ML
    Blackwood, MA
    Calzone, K
    Stopfer, J
    Campeau, L
    Ganguly, A
    Rebbeck, T
    Weber, BL
    Jablon, L
    Cobleigh, MA
    Hoskins, K
    Garber, JE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (20) : 1409 - 1415
  • [3] A simple system for automated two-dimensional electrophoresis: Applications to genetic testing
    Dhanda, RK
    Smith, WM
    Scott, CB
    Eng, C
    Vijg, J
    [J]. GENETIC TESTING, 1998, 2 (01): : 67 - 70
  • [4] Comparison of fluorescent single-strand conformation polymorphism analysis and denaturing high-performance liquid chromatography for detection of EXT1 and EXT2 mutations in hereditary multiple exostoses
    Dobson-Stone, C
    Cox, RD
    Lonie, L
    Southam, L
    Fraser, M
    Wise, C
    Bernier, F
    Hodgson, S
    Porter, DE
    Simpson, AHRW
    Monaco, AP
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2000, 8 (01) : 24 - 32
  • [5] Ellis LA, 2000, HUM MUTAT, V15, P556, DOI 10.1002/1098-1004(200006)15:6<556::AID-HUMU7>3.0.CO
  • [6] 2-C
  • [8] The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis
    Eng, C
    Clayton, D
    Schuffenecker, I
    Lenoir, G
    Cote, G
    Gagel, RF
    vanAmstel, HKP
    Lips, CJM
    Nishisho, I
    Takai, SI
    Marsh, DJ
    Robinson, BG
    FrankRaue, K
    Raue, F
    Xue, FY
    Noll, WW
    Romei, C
    Pacini, F
    Fink, M
    Niederle, B
    Zedenius, J
    Nordenskjold, M
    Komminoth, P
    Hendy, GN
    Gharib, H
    Thibodeau, SN
    Lacroix, A
    Frilling, A
    Ponder, BAJ
    Mulligan, LM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (19): : 1575 - 1579
  • [9] Genetic testing: The problems and the promise
    Eng, C
    Vijg, J
    [J]. NATURE BIOTECHNOLOGY, 1997, 15 (05) : 422 - 426
  • [10] From bench to bedside ... but when?
    Eng, C
    [J]. GENOME RESEARCH, 1997, 7 (07): : 669 - 672